Related Experiment Video
Updated: Dec 6, 2025
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
Mesoporous Silica Nanoparticles as Theranostic Antitumoral Nanomedicines
Alejandro Baeza1, Maria Vallet-Regí2
1Dpto. Materiales y Producción Aeroespacial, ETSI Aeronáutica y del Espacio, Universidad Politécnica de Madrid, 28040 Madrid, Spain.
Abstract:
Nanoparticles have become a powerful tool in oncology not only as carrier of the highly toxic chemotherapeutic drugs but also as imaging contrast agents that provide valuable information about the state of the disease and its progression. The enhanced permeation and retention effect for loaded nanocarriers in tumors allow substantial improvement of selectivity and safety of anticancer nanomedicines. Additionally, the possibility to design stimuli-responsive nanocarriers able to release their payload in response to specific stimuli provide an excellent control on the administered dosage. The aim of this review is not to present a comprehensive revision of the different theranostic mesoporous silica nanoparticles (MSN) which have been published in the recent years but just to describe a few selected examples to offer a panoramic view to the reader about the suitability and effectiveness of these nanocarriers in the oncology field.
Insights
Mesoporous silica nanoparticles (MSN) offer advanced cancer treatment by delivering chemotherapy drugs and acting as imaging agents. These nanoparticles enhance drug delivery, improve safety, and enable controlled release for effective oncology applications.
Area of Science:
- Oncology
- Nanomedicine
- Materials Science
Background:
- Nanoparticles are crucial in oncology for drug delivery and imaging.
- The enhanced permeation and retention (EPR) effect improves nanocarrier selectivity and safety in tumors.
- Stimuli-responsive nanocarriers allow controlled drug release and dosage management.
Purpose of the Study:
- To review the suitability and effectiveness of theranostic mesoporous silica nanoparticles (MSN) in oncology.
- To provide a panoramic view of selected MSN examples in cancer treatment and imaging.
- To highlight the potential of MSN as advanced nanocarriers in the oncology field.
Main Methods:
- Review of recent literature on theranostic mesoporous silica nanoparticles (MSN).
- Selection of representative examples showcasing MSN capabilities in oncology.
- Analysis of MSN properties related to drug delivery, imaging, and controlled release.
Main Results:
- MSN demonstrate significant potential as dual-purpose theranostic agents in oncology.
- The EPR effect is leveraged by MSN for improved tumor targeting and reduced systemic toxicity.
- Stimuli-responsive MSN offer precise control over drug release kinetics.
Conclusions:
- Mesoporous silica nanoparticles (MSN) are highly effective nanocarriers for cancer theranostics.
- MSN enhance the safety and efficacy of anticancer therapies through targeted delivery and controlled release.
- Further research into MSN holds promise for advancing personalized oncology treatments.
